fluphenazine decanoate LAI
Selected indexed studies
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (CNS Drugs, 2021) [PMID:33507525]
- Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation? (Curr Psychiatry Rep, 2025) [PMID:40289033]
- Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. (PLoS One, 2022) [PMID:35486616]
_Worker-drafted node — pending editorial review._
Connections
fluphenazine decanoate LAI is a side effect of
Sources
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (2021) pubmed
- Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation? (2025) pubmed
- Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. (2022) pubmed
- Long-Acting Injectable Antipsychotics in Children and Adolescents. (2017) pubmed
- The impact of fluphenazine withdrawal: a mirror-image study. (2024) pubmed
- Bioconversion and P-gp-Mediated Transport of Depot Fluphenazine Prodrugs after Intramuscular Injection. (2023) pubmed
- Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). (2013) pubmed
- Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. (2014) pubmed
- Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis. (2021) pubmed
- The use of first-generation long-acting injectable antipsychotics in children and adolescents-A retrospective audit from India. (2021) pubmed